Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2022

SAN DIEGO, May 12, 2022 /PRNewswire/ — Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced updates and…

Click here to view original post